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Since they were first proposed as nonviral transfection agents for their gene-carrying capacity, magnetic nanoparticles have been
studied thoroughly, both in vitro and in vivo. Great effort has been made to manufacture biocompatible magnetic nanoparticles
for use in the theragnosis of cancer and other diseases. Here we survey recent advances in the study of magnetic nanoparticles, as
well as the polymers and other coating layers currently available for gene therapy, their synthesis, and bioconjugation processes. In
addition, we review several gene therapy models based on magnetic nanoparticles.
1. Introduction
1.1. Cancer & Current Therapy. Although huge efforts have
led to advances in cancer treatment, this multifactorial and
heterogeneous disease is still one of the major causes of death
in the majority of countries [1–4]. Several factors influence
the high death rate of cancer patients around the world,
such as the genetic and phenotypic heterogeneity and the
highly unstable genomeof cancer cells, which ultimately leads
to continuously emerging, nonheterogeneous cells from the
tumor nest, and subsequent metastases [5].
Current cancer therapy encompasses a wide variety of
treatments from systemic cytostatics to targeted therapy
agents, most still in development phases, such as kinase
inhibitors [6–9], antibodies [10, 11], small molecules, or cell-
and antigen-based immunotherapies [12, 13]. Nevertheless,
most approved therapeutics require systemic administration,
which increases their toxicity and other clinical complica-
tions. One factor that eventually contributes to therapeutic
toxicity is nonspecificity. Guidance of drugs to the desired
tissue and specific target recognition are therefore major
concerns faced by cancer researchers seeking less toxic side
effects and improved efficiency of therapy.
Targeted strategies include ligand-receptor binding,
antibody-antigen specificity, and some other forms of
active targeting. For instance, several antibodies have been
developed that are directed to specific tumor-associated
antigens, either expressed uniquely by tumor cells or
overexpressed compared with healthy tissue; this is the case
of the HER2-specific antibody Herceptin [10], the VEGF-
specific antibody Bevacizumab [11], and ganglioside-specific
antibodies such as 14F7 [14].
Nanotechnology, and in particular a magnetic nanopar-
ticle-based approach, is a promising tool for the guidance of
therapeutic agents into tumor tissues.
1.2. Nanotechnology in Cancer Theragnosis. Use of nanotech-
nology is widespread in several fields of biomedicine due
to its potential in controlled drug delivery systems [15,
16], for diagnostic agents [17] and biosensors [18], among
other applications. The basis for their use in biomedicine
centers on the combination of their distinctive physical
properties, including their optical, electronic, and magnetic
behaviors. These properties arise from the combination of
two characteristics: a large surface area and the quantum
confinement effect due to the nanoscale sizes. Nanoparticles
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are usually coated with polymers or other coating layers that
could endow additional functions.
One promising physical property of nanosystems in
cancer biomedicine is their magnetism, especially superpara-
magnetism [19]. Two physical parameters theoretically define
magnetic materials, magnetization or magnetic polarization,
and the applied magnetic field (𝐻). When materials show
linear dependence between these two parameters as well as
low maximum magnetization, they are classified as weak
magnetic materials. In addition, these materials can be
subdivided into paramagnetic and diamagnetic substances,
depending on whether magnetization is positive or negative.
Strong magnetic materials differ from the above not
only in their high magnetization but also in their complex
behavior following exposure to an external magnetic field.
This behavior is described by the hysteresis loop. Strong
magnetic materials are classified as ferrimagnets, ferromag-
nets, and antiferromagnets, among others. There is a critical
temperature value (Curie temperature and Neel temperature
for ferrimagnets and antiferromagnets, resp.), below which
magnetic polarization increases up to saturation. Saturation
magnetization decreases as the temperature increases below
these critical values. Ferromagnets show remanent magneti-
zation when the external magnetic field is off. Above critical
temperature, these materials become superparamagnetic,
with a reversible magnetization curve (Figure 1) and zero
magnetic moment when the magnetic field is removed;
magnetic moments reach values more than 10 to 4 times
larger than those for paramagnetics if an external magnetic
field is applied.
Particles derived from the ferro/ferrimagnetic bulk state
and nanosized to as small as 1 to 30 nm diameter, depend-
ing on the material, behave superparamagnetically [20].
Nanosystems in this state basically show linear dependence
of magnetic susceptibility and applied magnetic field inten-
sity, as paramagnets do, but almost constant magnetization
once magnetic polarization is saturated. Superparamagnetic
nanosystems show no hysteresis and negligible remanent
magnetization.
Different areas or domains in which atoms are pinned in
the same direction commonly form ferromagnetic materials.
This phase separation is due to the gain of stability caused
by a decrease in magnetostatic energy as new domains arise
inside the bulk. The formation of new magnetic domains
nonetheless requires a certain amount energy, which con-
strains the size resulting from the break-bulk.This is because
the energy needed to form magnetic domains surpasses
the magnetostatic energy, making the process infeasible.
Below a certain size, a single-domain structure thus prevails.
Therefore, magnetic nanoparticles due to their size show a
single domain structure.
Magnetic nanoparticles are applied in cancer theragnosis
as contrast agents [21–23], for example, for magnetic
resonance images (MRIs). Superparamagnetic iron oxide
nanoparticles (SPIONs)must nonetheless be able to evade the
immune system to slow down their clearance from the blood-
stream and other biological fluids. SPIONs are eliminated
from the circulation mostly through the reticuloendothelial
system (RES) and renal clearance mechanisms [24–29].
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Figure 1: Magnetic behavior of materials as determined by relation-
ship between magnetization and applied magnetic field.
One factor that influences nanoparticle clearance is their
hydrodynamic size. In general, particles between 10 and
100 nm have the longest circulation time [30]; by contrast,
200 nm diameter particles tend to be eliminated by the RES,
and those with diameters <10 nm are removed mainly by
renal filtration.
Nanoparticle size also affects their ability to extravasate
from the bloodstream into tumor tissues, through the
socalled transcytosis process [31, 32]. This process depends
on particle size, with an upper limit of ∼150 nm. Another
important factor is the chemical nature of the nanoparticle
surface [33]. For instance, positive surface charge allows
nanoparticles to adhere nonspecifically to cell membranes
whilst negative surface charge leads to adsorption of plasma
proteins, thus increasing uptake and clearance via the RES
[34, 35]. Furthermore, plasma protein interaction with neg-
atively and positively charged nanoparticles induces different
biological responses [36]. Hydrophilic and neutral surfaces
endow nanoparticles with enhanced stealth, as they interact
less with blood proteins. The rationale and evidence for the
distinct factors that affect nanoparticle-biological interfaces
have been reviewed elsewhere [37].
Passive SPION-based cancer theragnosis relies on specific
features of the tumor microenvironment. These character-
istics allow nanoparticles to permeate tumor tissue without
extra active forces, though nanoparticle concentration can
be increased if such forces are used. The disorganized, leaky,
damaged vasculature of tumor tissue due to accelerated
angiogenesis facilitates SPION permeation of the tumor
microenvironment [38]. Once inside tumor tissue, nanopar-
ticles are retained due to the poorly developed lymphatic
vessels; this phenomenon is known as the enhanced perme-
ability and retention effect (EPR) (Figure 2). This high grade
of retention in tumor tissues allows most nanoparticles to be
taken up by tumor and stromal cells, including immune cells.
According to some reports, upper limits for macromolecule
size to show the EPR effect could be up to 1-2 𝜇m, as for
Lactobacillus sp. [39], which accumulate preferentially in
tumor tissues.
Modification of the tumor microenvironment is indeed
another way to achieve better nanoparticle uptake by malig-
nant cells.These approaches intend to increase the EPR effect
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Figure 2: The enhanced permeability retention effect (EPR) in a scenario of magnetic nanoparticle-based cancer therapy. Due to the weak
tumor vasculature, nanoparticles are able to permeate the tumor microenvironment, although clearance organs and the reticuloendothelial
system (RES) eliminate most. Polymers/moieties endow nanoparticles with stealth and specificity and thus with RES-evading capacity;
nanoparticle concentration in tumor tissue consequently increases. This nanoparticle accumulation in targeted tissue further increases as
an external magnetic field is applied.
inherent to solid tumors; for instance, application of a single
15Gy-radiation dose in a syngeneic mouse breast tumor
model doubled the accumulation of iron oxide nanoparticles
in tumor tissue [40]. This effect is associated with decreased
interstitial pressure and the subsequent increase in vascular
permeability and thus provides a new tool to improve drug
delivery into the tumor.
Various strategies have been studied to endow nanosys-
tems with stealth (Figure 2). For instance, when the propor-
tion of hydrophilic and hydrophobic polymers is changed
with negligible variation in particle size, the charges and
core composition of spontaneously self-assembled micelles
hindered their elimination by RES [41]. When tracked in
vivo, some of these micelles accumulated less in liver, while
they were more concentrated in blood at 1 h after intravenous
injection, as compared with PEGylated micelles.
2. Synthesis of Superparamagnetic Iron
Oxide Nanoparticles
According to the LaMer theory [42], nucleation and growth
processes for the formation of uniform nanoparticulates can
be divided into three phases. As the monomer concentration
increases, the system accumulates energy during phase I.
Once a supersaturated concentration is reached, the system
has sufficient energy for a nucleation burst that will be homo-
geneous; hence, a narrow-size dispersed colloid is obtained.
The presence of seeds such as crystallites in the medium
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Figure 3: The LaMer theory describes the synthesis of monodis-
perse nanoparticles. S and Sc are supersaturation and critical
supersaturation, respectively.
would induce heterogeneous nucleation, increasing the range
of nanoparticle diameters (Figure 3).
One of the most popular chemical methods for SPION
synthesis is based on coprecipitation of iron compounds [43–
47]. Two approaches can be used; the first takes advantage
of oxidizing agents such as nitrates [43] to induce partial
oxidation of ferrous hydroxidewhereas the second takes place
in an oxygen-free environment in which an alkaline suspen-
sion is added to an aqueous solution of ferrous (Fe2+) and
ferric (Fe3+) ions [44]. Using the second approach, Massart
obtained magnetic nanoparticles of ∼10 nm [44]. Using the
first approach, however, Sugimoto et al. obtained larger mag-
netic nanoparticles with diameters from 30 to 200 nm [43].
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Among factors affecting these methods, pH and ionic
strength contribute the most to the efficiency and quality
of the chemical reactions [43–47]. These parameters affect
nanoparticle size, in turn an indicator of their dispersion
stability.
Due to the properties of aqueousmicrodroplets that allow
the confinement of growth and agglomeration processes, the
microemulsion approach renders more uniform and smaller
nanoparticles [48, 49]. Assembly of surfactant-stabilized
aqueous microdroplets into an oil suspension that contain
iron precursors leads to controlled size SPION synthesis as
the precipitation of iron oxides occurs inside the confined
space [50]. Another suitable method for synthesis of uniform
nanoparticles is based on polyol. When reduced in a polyol
solution, metallic ions precipitate as metallic nanoparticles
with size ∼100 nm [51, 52]. Sun et al. reported similar results
when they synthesized 3 to 20 nm-diameter monodisperse
magnetic nanoparticles by thermal degradation of iron (III)
acetylacetonate in phenyl ether, in the presence of alcohol,
oleic acid, and oleylamine at 265∘C [53]. Other methods are
based on dendrimer platforms onto which SPION can be
precipitated uniformly [54] and on the use of high-energy
ultrasound waves [55, 56]; the application of these waves
induces hot empty spots that in turn randomly emit energetic
waves that eventually lead to a reduction in nanoparticle
size. Magnetic nanoparticles have also been synthesized by
electrochemical deposition of metal on a cathode, produced
by reduction of metal ions dissolved from the anode [57, 58],
similar to polyol-based synthesis.
Emerging tools for magnetic nanoparticle synthesis use
pyrolysis either by spraying a solution of Fe3+ salt and
reducing agents and subsequent vaporization of the droplets
obtained [59, 60], or by CO
2
laser heating of flowing gases
containing iron precursors [61, 62]. When a critical concen-
tration of nuclei is reached due to pressure and laser intensity,
the process of homogeneous nucleation of nanoparticles
begins. Iron pentacarbonyl is usually used as a precursor
for synthesis of 𝛾-Fe
2
O
3
nanoparticles by the laser-induced
pyrolysis method. Table 1 summarizes current methods for
magnetic core synthesis.
2.1. SPION Functionalization. SPIONs are coated with poly-
mers to confer colloidal suspendability. Polymers, such as
hydrophilic polymers, act as stabilizers or endow nanoparti-
cles with biocompatibility [63]. There can also be coupling of
physical properties of superparamagnetic core and polymeric
matrix.This coupling would depend on an external magnetic
field whose power is transferred to the surrounding matrix,
inducing conformational changes. The combination of mag-
netic nanoparticles with polymers sensitive to temperature
changes induced by an external magnetic field is thus of
interest [64–67].
Drug delivery systems combined withmagnetic nanosys-
tems have received constantly increasing attention (Figure 4).
The possibility of summing properties increases the efficiency
of drug delivery as well as the evasion of the immune system
and RES. One approach that has received particular attention
and effort is the magnetoliposome [65, 68–73]. Magnetic
Drug/fluorophore
Magnetic core 
Antibody
Polymer
DNA/RNA
Peptide/ligand
Lipid membrane 
Figure 4: Scheme of magnetic nanoparticles based on current
reports. Two main types of magnetic nanocarriers are depicted:
magnetoliposomes with a lipid membrane structure surround-
ing either a single magnetic core or a group of them, and a
biodegradable polymer encapsulating a single magnetic core or
group. Hydrophilic/hydrophobic balance defines the type of drug
that can be adsorbed, including genetic cargo. Molecular moieties
can be attached electrostatically or covalently.
nanoparticles can be embedded in the lipid bilayer or inside
the liposome, depending on the coating hydrophobicity [68–
73]. The former strategy might destabilize the bilayer by
physical movement rather than by heat dissipation; a lower
magnetic nanoparticle concentration is therefore needed to
induce drug release. Nanoparticle size must be controlled to
avoid further destabilization of the magnetoliposome, and
an appropriate coating is mandatory. The second approach
is more feasible due to the availability of hydrophilic layers,
but a larger number of magnetic nanoparticles are needed
to achieve the temperature increase and thus the lipid layer
destabilization that leads to drug release.
Using an external magnetic field,Mikhaylov et al. showed
that ferri-liposomes with SPION clusters encapsulated inside
liposomeswere able to reach tumor tissue in an immunocom-
petent tumor-bearing FVB/N mouse model [68]. Adminis-
tration of the cysteine cathepsin inhibitor JPM-565 embed-
ded in ferri-liposomes showed tumoricidal activity, as they
targeted not only tumor but also stromal cells. Moreover,
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Table 1: Summary of synthesis methods for magnetic nanoparticles and their features.
Method Temperature (∘C) Solvent Size range (nm) Morphology
Coprecipitation 20–90 Water 15–200 Spherical or rhombic
Microemulsions 20–50 Organic 4–12 Spherical or cubic
Hydrothermal synthesis 220 Water-ethanol 520 Spherical
Sol-gel synthesis 200–400 Organic 20–200 Spherical
Electrochemical deposition 70–100 Organic 3–8 Spherical
Sonochemical method 25 Water 10–30 Spherical or rod shaped
Polyol method 120–280 Organic 5–40 Spherical
Thermal decomposition 100–320 Organic 3–20 Spherical
Spray pyrolysis 400–700 Organic 5–60 Spherical but aggregated
Laser-induced pyrolysis 1100 Organic 5–30 Spherical less large
Biomimetic synthesis — 50–100 Spherical cluster, cubo-octahedral
better MRI sensitivity was observed, indicating another
function of these ferri-liposomes.
In another approach, the ability of iron oxide to dissipate
heat locally after exposure to an alternating magnetic field
was combined with the cargo-carrying property of liposomes
[74]. A distinct concept was tested in which magnetic
nanoparticles were not inside the liposome, but embedded
side by side in a calcium alginate hydrogel microparticle for
temperature-controlled drug release.
To design an early diagnostic method and targeted
therapy for pancreatic cancer, Deng et al. obtained ultrasmall
superparamagnetic iron oxide nanoparticles onto which
doxorubicin and antimesothelin antibody were inserted [75].
By targeting mesothelin-overexpressing pancreatic tumors,
these nanoparticles showed not only correct resonance con-
trast but also specific targeting in two models. Dimercapto-
succinic acid (DMSA)-coated magnetic nanoparticles have
likewise been tested for their ability to absorb IFN-𝛾 [76]
and their therapeutic efficiency in tumor immunotherapy.
These nanoparticles functioned correctly as an MRI agent
[77] and also markedly reduced tumor growth in a mouse
pancreatic tumor model (Pan02) [78]. IFN-𝛾 attachment
to the nanocarriers did not affect its function, as different
immune cell subsets such as T cells and macrophages were
detected in tumor niches.
Although a variety of functionalization methods have
been studied thoroughly, a general methodology can be
followed and materials used in the processes will depend on
the aim of the nanosystem. Most magnetic nanosystems are
coated with a layer that supplies the magnetic core with a
biocompatible, modifiable platform. If the goal is to use the
nanosystem as a diagnostic agent, for instance in MRI, no
other chemical processes will be needed, although further
modifications can be used to increase SPION ability to avoid
the RES.
Current and future perspectives address not only specific
targeting of nanosystems to tumor tissue but also transport
and controlled release of cargo; additionally, more com-
plex chemical modifications have been exploited to achieve
these goals. Some of these alterations include electrostatic
or covalent insertion of molecules. The chemical process
basically involves three types: direct conjugation, often used
to conjugate drugs or fluorescent molecules (Figure 5) [79–
81]; linker-mediated conjugation, which is suitable for ligand
attachment (Figure 6) [82–86]; and physical interaction-
mediated adsorption, best for assembling therapeutics such
as siRNA onto nanoparticle surfaces (Figure 7) [87–89].
Other methods can also be used, such as click chemistry
[90, 91] and hybridization [92, 93].
2.1.1. Making SPIONs Feasible for Gene Therapy. In addition
to the superparamagnetic features of SPION, other key prop-
erties must be present in the nanocarrier for correct cargo
delivery. For further conjugation, polymers must endow
SPION with reactivity to nucleic acids. This reactivity might
be based on physical interaction, that is, electrostatic forces,
or on reactive residues through which polymer and nucleic
acid react. Polymers onto which DNA or RNA will be
encapsulated must have a positive surface charge for the
electrostatic conjugation of nucleic acids; alternatively, both
polymer and nucleic acid must be modified with reactive
chemical residues for covalent conjugation. Although both
strategies have been used, the former is preferred, as it does
not modify nucleic acid integrity.
Once DNA/RNA is encapsulated onto SPION, the com-
plex must assure cargo stability and integrity. Nucleic acids
are very labile in the bloodstream and tissue microenviron-
ment, due to nucleases that recognize the 2-hydroxyl residue
of the sugar ring and catalyze alkaline hydrolysis [94]. Cell
uptake also plays a pivotal role in DNA elimination, for
example, in liver endothelial cells [95]. In addition, the encap-
sulationmust hamper TLR7/8 recognition of DNA/RNA [96,
97] to avoid an immune response to nanocarriers, leading to
early elimination from circulation.
Once at the tumor site, nanoparticles must be able to
permeate the tumor matrix. Polymers used for gene cargo
should protect nucleic acid from the acid microenvironment
that frequently surrounds tumor tissues. Tumor cells must
subsequently take up most of the nanocarriers that, once
internalized, must evade lysosomal degradation to deliver the
cargo into the cytosol.
Current problems with gene therapy in cancer are asso-
ciated with poor expression of the therapeutic agent, due to
6 ISRN Nanomaterials
N
HH
H
O
OO
N NH
H
H O
N
HH
O
O
O O
+
+
+
NH O
N N
H
O
O
O N
H
Amine
Aldehyde
Active hydrogen 
Succinimidyl ester 
Hydrazide
Amine
Mannich reaction 
Schiff-base condensation c
Direct conjugation
Figure 5: Representation of direct conjugation synthesis.
OH
O
Amine
Carboxyl
N
H
H
N O
O
N
O
O
O
O
N O
O
O
O
O
H
N
n
O
N
O
O
N O
O
O
O
S
S
N
N
O
O
O
O
I
SH
SH
+
SH
HS
O
H
N
H
N
H
N
N
H
O
N
O
O
S
O
O
H
N
n
O
N
O
O
S
O
S
S
O
SMCC
NHS-PEG-MAL
SDPD
SIA
Sulfhydryl
Sulfhydryl
Sulfhydryl
SATA-activated sulfhydryl 
LinkersMoieties
Linker-mediated conjugates
EDC/NHS activation
O
HN
Conjugates
NH2
Figure 6: Representation of indirect conjugation through linkers.
all of the biological barriersmentioned. A variety of polymers
has been developed for use in gene therapy, inwhich chemical
modification often leads to increased gene transfection both
in vitro and in in vivomodels.
Polyethylenimine (PEI), one of the most popular polyca-
tions for gene transfection, has beenmodifiedwith the amino
acids arginine (Arg), lysine (Lys), and leucine (Leu) [98].
Intravenous administration of these modified PEI com-
plexed with a 𝛽-galactosidase expression vector improved
gene expression efficiency by threefold compared with
the unmodified PEI polyplex. In another report, although
the oligo (benzylethylenimine)-b-polyethylenimine (OBzEI-
PEI) DNA complex profile was similar to its linear PEI
counterpart, OBzEI-PEI showed higher gene transfection
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efficiency in several cell lines despite decreased cell uptake
of plasmid [99]; the OBz-EI moiety also contributes to
the sponge effect of PEI, mediated by the pH-sensitive
membrane-disrupting activity.
In an attempt to elucidate the effect of the hydrophilic/
hydrophobic balance in PEI on function, Fan et al. reported
that transfection of HeLa cells with copolymers of different
degrees of hydrophobicity showed that Pluronic addition
enhances gene expression [100]. This effect is apparently
associated with homogeneous plasmid distribution in the
cytoplasm due to the greater hydrophilic/hydrophobic ratio
of Pluronics; in contrast, a lower ratio promoted nuclear
localization.
Linear PEI appears able to transfect cells efficiently in
vitro and in vivo. Goyal et al. synthesized a set of linear PEI
nanoparticles (lPEI, 25 kDa) by varying the percentage of
the crosslinker 1,4-butanediol diglycidyl ether (BDE) [101].
Compared with linear PEI and other available transfection
agents, all BDE-crosslinked linear PEI showed higher trans-
fection efficiency in terms of specific siRNA silencing of
GFP (Green Flourescent Protein). Although both polymers,
25 kDa branched PEI (b-PEI) and 22 kDa linear PEI (l-PEI),
are able to package DNA and siRNA, there are important
differences between them. First, the b-PEI/DNA complex is
less efficient than its l-PEI/DNA counterpart in the transfec-
tion of the luciferase gene.Whereas the bPEI/siRNA complex
induces gene knockdown, the l-PEI/siRNA silencing effect
is negligible [102], presumably due to poor stability of the
complexes.
In addition to the sponge effect of PEI, its combination
with other moieties that add new or enhanced properties to
complex has been exploited exhaustively. One goal of such
a strategy is to integrate gene therapy with other current
therapeutics. When ataxin-1 siRNA, in complex with PEGy-
lated chitosan modified with the cell membrane-penetrating
peptide TAT, was delivered in vitro to neurodegerative
spinocerebellar ataxia (SCA1) cell cultures, ataxin-1 was
downmodulated at 48 h after transfection [103]. Similarly,
PEI-PEG (polyethylene glycol) copolymers modified with
the TAT peptide and loaded with doxorubicin not only
packaged DNA but also delivered doxorubicin after acid
cleavage and penetrated the cell membrane,mediated by TAT
[104]. Adsorption of sulfamerazine (SA)-PEG-NGR on the
surface of the nanopolyplexes provided double targeting to
tumor vascular endothelial cells and tumor cells.
To increase PEI/DNA complex stability, He et al. estab-
lished PEI/DNA complexes with hyaluronic acid (HA), pre-
viously disulfide bond-modified or unmodified [105]. The
resulting complexes not only showed less cytotoxicity but
also increased transfection efficiency in HA receptor-positive
HepG2 and B16F10 cell lines.
An appropriate balance of modified primary PEI amines
is a key factor that affects DNA complexation, transfec-
tion, and PEI cytotoxicity. When carboxylated with bro-
moacetic, 6-bromohexanoic, 10-bromodecanoic, and 16-
bromohexadecanoic acid, the higher degree of PEI substitu-
tion or a longer alkyl chain was associated with decreased
DNA binding capacity [106]; cytotoxicity decreased con-
comitantly and transfection efficiency increased. In another
attempt to hinder the intrinsic cytotoxicity of PEI, Patnaik
et al. modified b-PEI/DNA by adsorption of hexametaphos-
phate [107]. The resulting polyplex protected DNA from
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DNases in vitro and efficiently transfected cells, either with
a GFP gene expression vector or with siRNA.
Despite its limited solubility in physiological media, the
linear polysaccharide chitosan has been thoroughly studied
as a gene delivery agent [108]. Toh et al. obtained succinylated
chitosans that were more efficient for gene transfection
compared with unmodified chitosan, with lower cytotoxicity
[109]. Chitosan has also been used as a polymeric material
for developing theranostic nanocarriers. Na et al. designed a
chitosan-based nanocomposite carrying Cy5.5 and paclitaxel
for live imaging and cancer treatment, respectively [110].
Theranostic nanoparticles require long-term stability in the
bloodstream and rapid uptake by tumor cells [111]. Other
cationic polymers used for gene transfection include HBP-
DEAPA 60, a biodegradable amine modified hyperbranched
polyester whose transfection efficiency was studied in A549
cells [112].
EPR underlies the passive targeting of most nanocarrier-
based cancer therapy although active targeting is needed to
increase the efficiency of these approaches. In the develop-
ment of a gene-carrier platform, some strategies for polymers
feasible for gene therapy require modification with targeting
moieties. Moieties such as antibody [113–115], peptides [116–
118], aptamers, and ligands [119] endow nanosystems with
tumor specificity. Apart from theEPRphenomenon andmag-
netic field application in the case of magnetic nanocarriers,
modification with targeting moieties consequently increases
nanocarrier concentration in tumor tissue and thus the in
vivo efficiency of gene therapy.
2.1.2. SPIONs as Gene Nanocarriers. The magnetic field-
dependent concentration of magnetic nanocarriers in a
desired site has drawn attention to their potential as gene
carriers. Magnetic nanocarriers not only protect genetic
cargo from degradation, but also deliver this cargo correctly
into targeted cells, thus resolving some problems of gene
therapy. Sincemagnetic nanoparticles were first proposed as a
feasible nonviral transfection agent [120, 121],magnetofection
(magnetic field-guided transfection) has been studied thor-
oughly in in vitro and in vivomodels.
Coating magnetic nanoparticles with PEG-g-PEI copoly-
mer rendered suitable nanocarriers for MRI function in
vivo in lung and liver [122]. These nanoparticles delivered
a siRNA against the CD44 variant 6, a putative marker for
metastatic behavior of gastric tumors, intracellularly into
the SCG-7901 cell line. Nevertheless, when tested in nude
mice bearing both SCG-7901 andA375-derived tumors, PEG-
g-PEI-SPION/siRNA complexes were unable to infiltrate
tumor tissue and thus did not contrast tumors adequately.
PEG-g-PEI-SPION delivered the IL-10 gene efficiently [123];
IL-10 expression triggered by magnetofection in primary
vascular cells (HUVEC) conditioned the medium to induce
downmodulation of TNF-𝛼-triggered PAI-1 expression in
these cells. PAI-1 is responsible for some vascular pathologies
such as inflammation and atherosclerosis.
Further modification of PEG-g-PEI-SPIONs by attach-
ment of a neuroblastoma-specific ligand (GD2 single chain
antibody) and BcL-2 siRNA was delivered in vitro and in
vivo to the SK.N-SH human neuroblastoma cell line [124].
The downodulation of BcL-2 induced an increase in cell
apoptosis rates and reduced tumor growthwhen the nanopar-
ticule complex was injected subcutaneously into SK-N-SH
tumor-bearing female mice.
Lee et al. developed thermally crosslinked SPION that
were subsequently modified with branched PEI of 1800Da
[125]. The p53 plasmid/PEI-coated SPION nanoplexes had a
hydrodynamic diameter ranging from 100 to 130 nm; in vitro
transfection of wild-type tumor suppressor p53 suppressed
tumor cell proliferation. Another report demonstrated the
suitability of low molecular weight PEI for gene therapy
by alkylating PEI 2 kDa and absorbing it onto magnetic
nanoparticles [126]. These nanoparticles were taken up in
vitro by fluc-4T1 murine mammary cancer cells (which
express luciferase), as determined by confocal laser imaging.
Once injected into the tumor, alkyl-PEI 2 kDa-magnetic
nanoparticles conjugated with siRNA specific for the elu-
ciferase gene, partially silenced luciferase activity, even after
a single shot. Second and third intratumor injections further
decreased the luciferase activity.
An interesting approach took advantage of the unique
properties of the socalled yolk-shell nanocapsules. These
nanosystems are composed of a magnetic core, interstitial
hollow spaces, and a shell. Zhang et al. proposed a Fe
3
O
4
magnetic core and a PEI-coated fluorescentmesoporous SiO
2
shell [127]. Nanoplexes obtained by attachment of 𝛽-actin
siRNA to the yolk-shell nanosystems efficiently silenced 𝛽-
actin in HeLa cells. In addition, the fluorescent shell allowed
nanoparticle tracking simultaneously with the magnetic
field-dependent guidance.
By combiningminicircle𝛽-galactosidaseDNAwithmag-
netic nanoparticles coated with a stearic acid-modified low
molecular weight PEI, Gao et al. were able to target the
liver [128]. As early as 3 h after intrabiliary infusion, accu-
mulation of magnetic nanoparticles was evident according
to T
2
-weighted images. Immunohistochemical analysis of 𝛽-
galactosidase expression and Prussian blue staining clearly
demonstrated that magnetic nanoparticles accumulated in
liver tissue and efficiently induced 𝛽-galactosidase expres-
sion.
In addition to PEI, other polymers have been used exten-
sively to coatmagnetic nanoparticles. Poly(maleic anhydride-
alt-1-decene)modifiedwith dimethylamino propylaminewas
used to coat hydrophobic magnetic nanoparticles [129]. The
presence of alternating hydrophilic and hydrophobic chains
provides an interface for interaction with the hydrophobic
surface of magnetic nanoparticles and carboxylic residues for
further conjugation of protamine, a cell-penetrating peptide.
The resulting magnetic nanosystem not only was less cyto-
toxic compared with popular gene transfection agents such as
PEI and lipofectamine but also more efficiently silenced the
GFP gene in U251 cells in a serum-containing medium.
To treat adenoid cystic carcinoma, Miao et al. developed
PEI-coated Fe
3
O
4
nanoparticles onto which the pACTERT-
TRAIL plasmid, a human telomerase reverse transcription
promoter-driven TRIAL expression plasmid, was adsorbed
electrostatically [130]. The nanocomplex triggered TRIAL
expression in SACC-83 cells in vitro and in vivo andultimately
increased the apoptosis rate.
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The commercially available magnetic nanocarrier Com-
biMAG was also tested for its gene delivery capacity. Kong
et al. demonstrated that the magnetoplex composed of Com-
biMAG and IGF-1R-specific shRNA was delivered efficiently
into A549 cells in vitro, with inhibition of proliferation,
adhesion, and chemoresistance [131–134]. A magnetoplex
CombiMAG bearing the plasmid pGFPshIGRR1 that drives
the concomitant expression of green fluorescent protein and
the IGF-R1-specific shRNA was injected into mice via the tail
vein; as early as 48 h post-injection, GFP expression peaked
in several organs including heart, kidney, and lung [135].
IGFR1 expression decreased as early as 48 h after injection,
as determined by western blot of explanted tumor tissue and
immunohistochemistry analysis.
An interesting approach paired magnetic nanocarriers
and the ultrasound microbubble technology [136]. Lipid
microbubbles were coated with PEI-attached magnetic
nanoparticles and a dsRed DNA plasmid was subsequently
adsorbed. In a dorsal skin-fold chamber model to visualize
vessel network by intravital microscopy in BL6 mice, injec-
tion of the pdsRed/PEI-coated NPs/microbubble complex
delivered the genetic cargo only when both magnetic and
ultrasound forces were applied in the dorsal skin. No other
vascular walls were affected, indicating precise, site-specific,
and ultrasound-controlled delivery of genetic cargo through
the vasculature system.
Others nanocarriers suitable for DNA/siRNA delivery
were obtained by coating a magnetic core with lipoids,
a cationic lipid [137]. By monitoring GFP expression or
luciferase activity in luciferase siRNA-treated cells, lipoid-
coated magnetic nanoparticles were found to deliver both
nucleic acids. The efficiency of gene expression and siRNA-
mediated luciferase silencing increased greatly when an
external magnetic filed was applied. Mok et al. developed a
magnetic nanosystem composed of pH-sensitive branched
PEI to exploit the low pH normally found in the tumor
microenvironment [138]. Once conjugated with the tumor-
specific peptide chlorotoxin and a siRNA against GFP, the
nanosystem silenced GFP; in addition, its efficiency was
highly dependent on the acidic conditions surrounding
tumor cells.
To silence the epidermal growth factor receptor (EGFR)
in tumor-infiltrating vessels, the nanocompound LipoMag
was used as carrier for EGFR-specific siRNA [139]. When
tested in vivo, LipoMag complexed with EGFR siRNA
reduced the tumor burden in nude mice inoculated with
MKN-74 or NUGC-4 as compared with commercially avail-
able PolyMag.
An important hurdle for gene therapy is gene transfection
efficiency in physiological conditions, where soluble factors
can hinder appropriate delivery of the nanovector. Magnetic
nanoparticles developed by physical interaction between pre-
viously polyacrylic acid-coated magnetic nanoparticles and
PEI demonstrated increased gene expression in the presence
of 10% fetal bovine serum when an external magnetic field
was applied [140].
One emerging gene nanocarrier is derived from the com-
bination of magnetic nanoparticles and viral agents. Tested
on HEK293T cells, both heparin- and streptavidin-coated
magnetic nanoparticles onto which adenovirus vectors
(AVVs) were adsorbed directly or through a biotin-Ni-His
6
link, respectively, enhanced AVV-driven GFP expression
when a magnetic field was applied [141, 142]. Strikingly,
a heparin-coated Fe
3
O
4
/AVV-driven neuron growth factor
(NGF) expression nanocomplex wasmore efficient thanNGF
itself in neurite elongation, as seen in the pheochromocytoma
of PC12 rat adrenal medulla cells [141]. For the in vitro
transfection of poorly transfectable human neuron stem cells,
theAVV-His
6
-Ni-biotin/streptavidinmagnetic nanoparticles
showed enhanced internalization and gene expression com-
paredwithAVValone [142]. Sapet et al. enhanced in vivo gene
expression in rat hippocampal neuronsusing a type 5 AVV
carrying a CMV-driven GFP expression cassette associated
with magnetic nanoparticles [143].
3. Conclusions and Future Challenges
Magnetic nanoparticle technology offers an enormous field
for gene therapy, especially in cancer treatment. Finding
new polymers or improving those currently available as gene
carriers is the goal of scientists; the development of new
synthesis methods has accelerated this process. Important
questions remain to be addressed, such as the escalation of
magnetic nanocarrier manufacture and cytotoxicity to attain
regulatory approval. Once these two elements are resolved,
clinical trials can be undertaken.
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